Fractyl Health, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsFractyl Health is a clinical-stage metabolic therapeutics company developing Revita, a duodenal mucosal resurfacing device for post-GLP-1 weight maintenance, and Rejuva, an AAV-delivered pancreatic gene therapy for type 2 diabetes and obesity.
What they do
Fractyl Health is developing two lead candidates: Revita, a hydrothermal ablation device designed to remodel the duodenal lining to restore nutrient sensing and maintain weight loss after GLP-1 discontinuation, and Rejuva, a locally administered AAV gene therapy platform aimed at durable remission of type 2 diabetes and obesity. The company has no approved products in the U.S. and has not generated product revenue; it received CE mark for Revita in Europe in 2016 and has reimbursement authorization via NUB in Germany for T2D treatment. The REMAIN-1 program, conducted under a single IDE, includes the REVEAL-1 Cohort (n=22), the REMAIN-1 Midpoint Cohort (n=45), and the REMAIN-1 Pivotal Cohort (n=315), all fully enrolled and randomized. The company paused additional investment in Revita for T2D (REVITALIZE-1 and Germany Real-World Registry) but continues to follow existing participants.
Revenue drivers
- Revita — Lead product candidate; no product revenue yet. Potential market in post-GLP-1 weight maintenance; U.S. FDA Breakthrough Device designation; De Novo submission anticipated late Q4 2026.
- Rejuva — Preclinical/clinical stage gene therapy platform; no revenue. R&D expenses were $3.9M in H1 2026, lower than $7.9M in H1 2025 due to reduced manufacturing and preclinical spending.
- Commercial infrastructure — Building capabilities for future Revita launch; appointed SVP of Market Access in June 2026; no sales yet.
Recent performance
For Q2 2026, Fractyl reported a net loss of $25.5 million, compared to $27.9 million in Q2 2025, with R&D expenses down 34.7% to $13.8 million. For H1 2026, R&D expenses were $29.4 million versus $40.6 million in H1 2025. As of June 30, 2026, cash and equivalents were $47.1 million, total assets $82.0 million, total liabilities $83.6 million, and shareholder equity was negative $1.7 million. The company has incurred net losses since inception, with an accumulated deficit of approximately $556.3 million at year-end 2025.
Strategy
Fractyl is focused on completing the REMAIN-1 pivotal program and submitting a De Novo application for Revita in post-GLP-1 weight maintenance. It is building commercial infrastructure, including market access leadership, and plans an Investor Day in September 2026 to detail commercial strategy. The company paused additional investment in Revita for T2D to prioritize weight maintenance. It continues to advance Rejuva toward clinical readiness, though spending decreased in 2026.
Risks
- Going concern — The company has identified conditions and events that raise substantial doubt about its ability to continue as a going concern.
- No revenue — No products approved for commercial sale in the U.S. and no product sales revenue to date.
- Regulatory failure — Potential failure to complete pivotal studies or obtain FDA marketing authorization (De Novo) for Revita.
- Cash runway — Cash runway guidance into early 2027; may need additional funding to reach profitability, which is uncertain.
Outlook
Management expects topline six-month data from the REMAIN-1 Pivotal Cohort in early Q4 2026, with potential FDA De Novo submission in late Q4 2026. Cash runway is guided into early 2027, covering anticipated milestones. The company reiterated all previously disclosed 2026 clinical and regulatory milestones.